Ionis to Seek Expedited FDA Review for ALS Drug

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Otsuka on Tuesday shared positive topline results from their Phase 3 FUSION trial. The trial evaluated ulefnersen, an investigational RNA-targeted medicine, in patients with amyotrophic lateral sclerosis (ALS) caused by...